Lyon, France, May 12, 2020 – MaaT Pharma announced today the appointment of leading international experts in the field of…
Categorie
2020
In response to the recent “FDA Safety Alert Regarding Use of Fecal Microbiota for Transplantation and Risk of Serious Adverse…
March 13, 2020
Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused…
January 31, 2020
Lyon, France, February 5, 2020 – MaaT Pharma announced today an €18 million Series B financing round including a microbiome-focused…
January 31, 2020
We are a clinical-stage microbiome therapeutics company aiming to improve survival in cancer.
Ressources
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.
Contact
Nous sommes une société au stade clinique, spécialisée dans les thérapies issues du microbiote dédiées aux patients atteints de cancer.